- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02099136
Celecoxib in Preventing the Damaging Effects of Sunburn in Healthy Volunteers
Clinical Protocol for a Double-Blind, Placebo-Controlled, Randomized Dose-Ranging Study of Celecoxib (SC-58635) on the Acute Effect of Human UV-Irradiation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Quantify changes in the erythema response in human subjects exposed to minimally erythemic doses of solar-simulated ultraviolet light before and after celecoxib treatment.
II. Determine the effect of celecoxib on various biomarkers following ultraviolet (UV)-irradiation. The modulation of the following biomarkers, before and after treatment with celecoxib are being examined: apoptosis and proliferation indices, prostaglandin E2 (PGE2), cyclooxygenase-1 (COX-1), and cyclooxygenase- 2 (COX-2) levels.
OUTLINE:
Patients undergo UV-irradiation to the right buttock at baseline. Chromameter readings are obtained at 24 hours post UV-irradiation and patients undergo skin biopsy at 24 and 96 hours following UV-irradiation.
Patients are then randomized to 1 of 5 treatment groups.
GROUP I: Patients receive placebo orally (PO) twice daily (BID) for 14 days.
GROUP II: Patients receive low-dose celecoxib PO BID for 14 days.
GROUP III: Patients receive higher dose celecoxib PO BID for 14 days.
GROUP IV: Patients receive same dose of celecoxib PO as Group III once daily (QD) for 14 days.
GROUP V: Patients receive high-dose celecoxib PO QD for 14 days.
After 10 days post-treatment, patients undergo UV-irradiation to the left buttock. Chromameter readings are obtained at 24 hours post UV-irradiation and patients undergo skin biopsy at 24 and 96 hours following UV-irradiation.
After completion of study treatment, patients are followed up at day 25.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
Rochester, New York, United States, 14642
- University of Rochester
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The subject as Fitzpatrick skin type I, II, or III
If the subject is female and of childbearing potential (women are considered not of childbearing potential if they are at least 2 years post-menopausal and/or surgically sterile):
- Has been using adequate contraception (e.g., condom, intrauterine device [IUD], diaphragm and spermicide gel combination) since her last menses and will use adequate contraception during the study, AND
- Is not lactating, AND
- Has had a negative pregnancy test (serum or urine) within 14 days prior to the first dose of study medication
- The subject is willing to abstain from the use of non-steroidal anti-inflammatory drugs (NSAIDs) for the duration of the study
- The subject is willing to abstain from the use of all topical agents applied to the buttocks for the duration of the study
- The subject is willing to participate for the duration of the study
- The subject has provided written informed consent prior to administration of any study related procedures
Exclusion Criteria:
- The subject is currently taking any medication that may alter the sunlight response or cause an adverse reaction
- The subject has a history of melanoma, lupus, psoriasis, rosacea, porphyria, photosensitivity disorder, keloid formation, connective tissue disorder, or any disease that would increase the risk associated with study participation
- The subject has excessive hair, blemishes, nevi, uneven pigmentation, sunburn or suntan on the buttocks
- The subject has sun bathed or used a tanning bed to expose the buttocks within 12 months of admission to the study
- The subject has inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), a chronic or acute renal or hepatic disorder or a significant coagulation defect or any other condition which in the investigator's opinion might preclude use of an NSAID (e.g., congestive heart failure)
- The subject has an active malignancy of any type or history; subjects who have a history of nonmelanoma skin cancer and have been treated are acceptable; subjects with a history of other malignancies that have been surgically removed and who have no evidence of recurrence for at least five years prior to study enrollment are also acceptable
- The subject has active or suspected peptic ulceration or gastrointestinal bleeding
- The subject has abnormal baseline laboratory test > 1.5 x upper limit of normal (ULN) for serum glutamic oxaloacetic transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT), creatinine, and/or blood urea nitrogen (BUN); all other laboratory abnormalities at baseline thought by the investigator to be clinically significant are also basis for exclusion
- The subject has received any investigational medication within 30 days prior to the first dose of study medication or is scheduled to receive an investigational drug other than celecoxib during the course of this study
- The subject has known hypersensitivity to cyclooxygenase-2 inhibitors, sulfonamides, or NSAIDs
- The subject has been previously admitted to this study
- The subject has significant medical or psychosocial problems that would make the subject a poor candidate, in the opinion of the principal investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Group I (placebo)
Patients receive placebo PO BID for 14 days.
|
Given PO
Other Names:
Undergo skin biopsy
Other Names:
Undergo UV-irradiation
Other Names:
Correlative studies
|
EXPERIMENTAL: Group II (low-dose celecoxib)
Patients receive low-dose celecoxib PO BID for 14 days.
|
Given PO
Other Names:
Undergo skin biopsy
Other Names:
Undergo UV-irradiation
Other Names:
Correlative studies
|
EXPERIMENTAL: Group III (higher dose celecoxib BID)
Patients receive higher dose celecoxib PO BID for 14 days.
|
Given PO
Other Names:
Undergo skin biopsy
Other Names:
Undergo UV-irradiation
Other Names:
Correlative studies
|
EXPERIMENTAL: Group IV (higher dose celecoxib QD)
Patients receive same dose of celecoxib PO as Group III QD for 14 days.
|
Given PO
Other Names:
Undergo skin biopsy
Other Names:
Undergo UV-irradiation
Other Names:
Correlative studies
|
EXPERIMENTAL: Group V (high-dose celecoxib)
Patients receive high-dose celecoxib PO QD for 14 days.
|
Given PO
Other Names:
Undergo skin biopsy
Other Names:
Undergo UV-irradiation
Other Names:
Correlative studies
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent change in erythema
Time Frame: Baseline up to day 25
|
Descriptive statistics such as mean, median and standard deviation will be calculated.
An increase of 50% in the UV dose needed to reach the minimal erythema dose (MED) will be considered preliminary evidence of drug activity.
The modulation of the biomarkers will be compared to the shift in the erythema response.
Summary statistics will be provided for plasma drug levels.
|
Baseline up to day 25
|
Percent change in PGE2
Time Frame: Baseline up to day 25
|
Descriptive statistics such as mean, median and standard deviation will be calculated.
An increase of 50% in the UV dose needed to reach the MED will be considered preliminary evidence of drug activity.
The modulation of the biomarkers will be compared to the shift in the erythema response.
Summary statistics will be provided for plasma drug levels.
|
Baseline up to day 25
|
Percent change in COX-1
Time Frame: Baseline up to day 25
|
Descriptive statistics such as mean, median and standard deviation will be calculated.
An increase of 50% in the UV dose needed to reach the MED will be considered preliminary evidence of drug activity.
The modulation of the biomarkers will be compared to the shift in the erythema response.
Summary statistics will be provided for plasma drug levels.
|
Baseline up to day 25
|
Percent change in COX-2
Time Frame: Baseline up to day 25
|
Descriptive statistics such as mean, median and standard deviation will be calculated.
An increase of 50% in the UV dose needed to reach the MED will be considered preliminary evidence of drug activity.
The modulation of the biomarkers will be compared to the shift in the erythema response.
Summary statistics will be provided for plasma drug levels.
|
Baseline up to day 25
|
Percent change in proliferative index
Time Frame: Baseline up to day 25
|
Descriptive statistics such as mean, median and standard deviation will be calculated.
An increase of 50% in the UV dose needed to reach the MED will be considered preliminary evidence of drug activity.
The modulation of the biomarkers will be compared to the shift in the erythema response.
Summary statistics will be provided for plasma drug levels.
|
Baseline up to day 25
|
Percent change in apoptotic index
Time Frame: Baseline up to day 25
|
Descriptive statistics such as mean, median and standard deviation will be calculated.
An increase of 50% in the UV dose needed to reach the MED will be considered preliminary evidence of drug activity.
The modulation of the biomarkers will be compared to the shift in the erythema response.
Summary statistics will be provided for plasma drug levels.
|
Baseline up to day 25
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Cyclooxygenase 2 Inhibitors
- Celecoxib
Other Study ID Numbers
- NCI-2014-00525 (REGISTRY: CTRP (Clinical Trial Reporting Program))
- NQ4-99-02-008 (OTHER: University of Rochester)
- N01-CN-85183-Step1 (OTHER: DCP)
- N01CN85183 (Other Identifier: US NIH Grant/Contract Award Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on No Evidence of Disease
-
National Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)CompletedHealthy, no Evidence of DiseaseUnited States
-
Cancer Research UKUnknownHealthy, no Evidence of DiseaseUnited Kingdom
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedHealthy, no Evidence of DiseaseUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedHealthy, No Evidence of DiseaseUnited States
-
National Cancer Institute (NCI)CompletedHealthy, no Evidence of DiseaseUnited States
-
National Cancer Institute (NCI)TerminatedHealthy, no Evidence of DiseaseUnited States
-
National Cancer Institute (NCI)CompletedHealthy, no Evidence of DiseaseUnited States
-
National Cancer Institute (NCI)CompletedHealthy, no Evidence of DiseaseUnited States
-
National Cancer Institute (NCI)Completed
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States